Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Foghorn Therapeutics (Nasdaq: FHTX), a clinical-stage biotech company focused on developing medicines that correct abnormal gene expression, has announced its participation in three upcoming investor conferences in September 2025.
The company will attend Citi's 2025 Biopharma Back to School Summit on September 3, the 2025 Wells Fargo Healthcare Conference on September 4, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8. Management will conduct one-on-one meetings at all three events.
Foghorn's Gene Traffic Control庐 platform focuses initially on oncology applications, aiming to develop treatments for a broad spectrum of diseases.
Foghorn Therapeutics (Nasdaq: FHTX), una societ脿 biotech in fase clinica focalizzata sullo sviluppo di farmaci che correggono l'espressione genica anomala, ha annunciato la sua partecipazione a tre prossimi convegni per investitori a settembre 2025.
La societ脿 parteciper脿 al Citi's 2025 Biopharma Back to School Summit il 3 settembre, al 2025 Wells Fargo Healthcare Conference il 4 settembre e al Morgan Stanley 23rd Annual Global Healthcare Conference l'8 settembre. Il management terr脿 incontri one-to-one in tutti e tre gli eventi.
La piattaforma Gene Traffic Control庐 di Foghorn si concentra inizialmente sulle applicazioni in oncologia, con l'obiettivo di sviluppare terapie per un ampio spettro di malattie.
Foghorn Therapeutics (Nasdaq: FHTX), una biotecnol贸gica en fase cl铆nica centrada en desarrollar medicamentos que corrigen la expresi贸n g茅nica an贸mala, ha anunciado su participaci贸n en tres pr贸ximas conferencias para inversores en septiembre de 2025.
La compa帽铆a asistir谩 al Citi's 2025 Biopharma Back to School Summit el 3 de septiembre, al 2025 Wells Fargo Healthcare Conference el 4 de septiembre y al Morgan Stanley 23rd Annual Global Healthcare Conference el 8 de septiembre. La direcci贸n mantendr谩 reuniones one-to-one en los tres eventos.
La plataforma Gene Traffic Control庐 de Foghorn se orienta inicialmente a aplicaciones en oncolog铆a, con la meta de desarrollar tratamientos para un amplio espectro de enfermedades.
Foghorn Therapeutics (雮橃姢雼�: FHTX)電� 牍勳爼靸侅爜鞚� 鞙犾爠鞛� 氚滍槃鞚� 甑愳爼頃橂姅 鞎诫 臧滊皽鞐� 欷戩爯鞚� 霊� 鞛勳儊 雼硠 氚旍澊鞓ろ厤鞙茧, 2025雲� 9鞗� 臧滌禍霅橂姅 靹� 瓯挫潣 韴瀽鞛� 旎嵓霟办姢鞐� 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
須岇偓電� 9鞗� 3鞚� Citi's 2025 Biopharma Back to School Summit, 9鞗� 4鞚� 2025 Wells Fargo Healthcare Conference, 9鞗� 8鞚� Morgan Stanley 23rd Annual Global Healthcare Conference鞐� 彀胳劃頃� 鞓堨爼鞚措┌, 瓴届榿歆勳潃 靹� 頄夓偓 氇憪鞐愳劀 1:1 氙疙寘鞚� 歆勴枆頃╇媹雼�.
Foghorn鞚� Gene Traffic Control庐 頂岆灚韽检潃 齑堦赴鞐愲姅 鞎�(膦呾枒頃�) 鞝侅毄鞐� 欷戩爯鞚� 霊愱碃 鞛堨溂氅�, 雱撿潃 氩旍渼鞚� 歆堩櫂鞐� 雽�頃� 旃橂鞝� 臧滊皽鞚� 氇╉憸搿� 頃橁碃 鞛堨姷雼堧嫟.
Foghorn Therapeutics (Nasdaq: FHTX), une soci茅t茅 de biotechnologie en phase clinique sp茅cialis茅e dans le d茅veloppement de m茅dicaments corrigeant l'expression g茅nique anormale, a annonc茅 sa participation 脿 trois prochaines conf茅rences investisseurs en septembre 2025.
La soci茅t茅 assistera au Citi's 2025 Biopharma Back to School Summit le 3 septembre, 脿 la 2025 Wells Fargo Healthcare Conference le 4 septembre et 脿 la Morgan Stanley 23rd Annual Global Healthcare Conference le 8 septembre. La direction tiendra des r茅unions individuelles lors des trois 茅v茅nements.
La plateforme Gene Traffic Control庐 de Foghorn se concentre initialement sur des applications en oncologie, visant 脿 d茅velopper des traitements pour un large 茅ventail de maladies.
Foghorn Therapeutics (Nasdaq: FHTX), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Medikamenten zur Korrektur abnormer Genexpression konzentriert, hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen im September 2025 angek眉ndigt.
Das Unternehmen wird am Citi's 2025 Biopharma Back to School Summit am 3. September, an der 2025 Wells Fargo Healthcare Conference am 4. September und an der Morgan Stanley 23rd Annual Global Healthcare Conference am 8. September teilnehmen. Das Management wird bei allen drei Veranstaltungen Einzelgespr盲che f眉hren.
Foghorns Gene Traffic Control庐-Plattform konzentriert sich zun盲chst auf Anwendungen in der Onkologie und zielt darauf ab, Therapien f眉r ein breites Spektrum von Erkrankungen zu entwickeln.
- None.
- None.
CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- August 27, 2025 -- Foghorn庐 Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Citi鈥檚 2025 Biopharma Back to School Summit, 2025 Wells Fargo Healthcare Conference, and Morgan Stanley 23rd Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn鈥檚 Gene Traffic Control庐聽platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Citi鈥檚 2025 Biopharma Back to School Summit
- Date: Wednesday, September 3, 2025
- Management will participate in one-on-one meetings
2025 Wells Fargo Healthcare Conference
- Date: Thursday, September 4, 2025
- Management will participate in one-on-one meetings
Morgan Stanley 23rd Annual Global Healthcare Conference
- Date: Monday, September 8, 2025
- Management will participate in one-on-one meetings
About Foghorn Therapeutics
Foghorn庐 Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control庐 platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at聽聽for more information on the Company, and follow us on聽听补苍诲听.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
[email protected]
FAQ
When is Foghorn Therapeutics (FHTX) presenting at the Wells Fargo Healthcare Conference 2025?
What conferences will Foghorn Therapeutics (FHTX) attend in September 2025?
What is Foghorn Therapeutics' (FHTX) main technology platform?
How can investors meet with Foghorn Therapeutics (FHTX) management at these conferences?
